Education
About Us
Working with TipRanks
Follow Us
Ceribell, Inc. (CBLL)
NASDAQ:CBLL
Earnings Data
Report Date
Nov 18, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
―Last Year’s EPS
-1.85Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -6.61%
|Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, high gross margins, expansion of active accounts, and important regulatory achievements, such as FDA clearance and FedRAMP authorization. However, the increase in operating expenses and net loss, along with potential impacts from increased tariffs, present challenges. Despite these lowlights, the positive aspects, including strategic achievements and financial growth, suggest a confident outlook.Company Guidance
In the CeriBell, Inc. Q1 2025 earnings call, the company reported a robust start to the year with total revenue of $20.5 million, marking a 42% increase compared to the same period last year. The company experienced 88% gross margin, reflecting its strategic success in account acquisition and utilization. CeriBell added 29 new accounts, reaching a total of 558 active accounts, including its first cohort of VA hospitals. The company also received FedRAMP high authorization, enhancing its cybersecurity credentials. For 2025, CeriBell raised its revenue guidance to $83-$87 million, reflecting an annual growth of 27% to 33%. Despite potential tariff impacts, the company expects to maintain gross margins in the mid-80% range, leveraging its U.S. inventory and cost reduction strategies. The company is also confident in reaching cash flow breakeven with its current cash on hand, totaling $182.7 million as of March 31, 2025.Strong Revenue Growth
CeriBell, Inc. reported total revenue of $20.5 million for Q1 2025, marking a 42% increase over the same period last year and an 11% increase over Q4 2024.
High Gross Margin
The company achieved a gross margin of 88% in Q1 2025, compared to 86% in the prior year period, indicating strong profitability.
Expansion of Active Accounts
The company increased its active accounts to 558 as of March 31, 2025, adding 29 new accounts in Q1, including the integration of its clarity algorithm in VA hospitals.
FDA Clearance and Product Expansion
CeriBell, Inc. received FDA 510(k) clearance for its Clarity algorithm for seizure detection in pediatric patients, expanding the addressable patient population significantly.
FedRAMP High Authorization Achieved
CeriBell, Inc. received FedRAMP high authorization from the US government, validating its cybersecurity standards and enabling use by other government agencies.
---
CBLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CBLL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $17.10 | $15.97 | -6.61% |
Feb 25, 2025 | $25.54 | $25.20 | -1.33% |
Nov 12, 2024 | $28.85 | $27.88 | -3.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ceribell, Inc. (CBLL) report earnings?
Ceribell, Inc. (CBLL) is schdueled to report earning on Nov 18, 2025, TBA Not Confirmed.
What is Ceribell, Inc. (CBLL) earnings time?
Ceribell, Inc. (CBLL) earnings time is at Nov 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CBLL EPS forecast?
Currently, no data Available
---